(Q37157232)

English

CTLA-4: negative regulator of the immune response and a target for cancer therapy

scientific article published on June 2008

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18 August 2017

1 reference

Europe PubMed Central

title

CTLA-4: negative regulator of the immune response and a target for cancer therapy (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18 August 2017

Ulrich Keilholz

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18463542

retrieved

18 August 2017

publication date

1 June 2008

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18463542

retrieved

18 August 2017

published in

Journal of Immunotherapy

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18463542

retrieved

18 August 2017

volume

31

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18463542

retrieved

18 August 2017

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18463542

retrieved

18 August 2017

page(s)

431-439

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18463542

retrieved

18 August 2017

cites work

Results of a phase II clinical trial of 2 doses and schedules of CP-675,206, an anti-CTLA4 monoclonal antibody, in patients (pts) with advanced melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.3000

Durable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanoma

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2005.23.16_SUPPL.7525

A phase II study of the anti-CTLA4 monoclonal antibody (mAb), CP-675,206, in patients with refractory metastatic adenocarcinoma of the colon or rectum

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.3035

Biochemical and immunologic correlates of clinical response in a combination trial of the GM-CSF-gene transduced allogeneic prostate cancer immunotherapy and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)

1 reference

18 October 2022

https://opencitations.net/index/coci/api/v1/citations/10.1200/JCO.2007.25.18_SUPPL.5120

Identifiers

DOI

10.1097/CJI.0B013E318174A4FE

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18463542

retrieved

18 August 2017

PubMed publication ID

18463542

1 reference

stated in

Europe PubMed Central

PubMed publication ID

18463542

retrieved

18 August 2017

(Q37157232)

CTLA-4: negative regulator of the immune response and a target for cancer therapy

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)